Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review
BackgroundGouty arthritis (GA) is a crystal-related joint disease caused by the deposition of monosodium urate (MSU) crystals, directly associated with hyperuricemia resulting from purine metabolism disorder and/or reduced uric acid excretion. Acute attacks of typical gouty arthritis are generally r...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1357117/full |
| _version_ | 1797238488675909632 |
|---|---|
| author | Lishi Yu Weidong Huang Honghua Lv Lie Jin Wenhui Lei |
| author_facet | Lishi Yu Weidong Huang Honghua Lv Lie Jin Wenhui Lei |
| author_sort | Lishi Yu |
| collection | DOAJ |
| description | BackgroundGouty arthritis (GA) is a crystal-related joint disease caused by the deposition of monosodium urate (MSU) crystals, directly associated with hyperuricemia resulting from purine metabolism disorder and/or reduced uric acid excretion. Acute attacks of typical gouty arthritis are generally relieved through the clinical use of NSAIDs, colchicine, or glucocorticoids. However, managing patients with chronic refractory gout poses challenges due to complications such as multiple tophi, gouty nephropathy, diabetes, and gastrointestinal bleeding. While there have been numerous studies on gout in recent years, research specifically regarding chronic refractory gout remains limited. The management of such cases still faces several unresolved issues, including recurrent disease flare-ups and poor patient compliance leading to inadequate drug utilization and increased risk of side effects. In this report, we present a case of successful improvement in chronic refractory gouty arthritis using the biologic agent upadacitinib sustained-release tablets.Case presentationOur case report involves a 53 years-old Asian patient with recurrent gouty arthritis who had a history of over 20 years without regular treatment, presenting with tophi and an increasing number of painful episodes. During hospitalization, various analgesics and anti-inflammatory drugs provided inadequate relief, requiring the use of steroids to alleviate symptoms. However, tapering off steroids proved challenging. We decided to add upadacitinib sustained-release tablets to the treatment regimen, which ultimately improved the patient’s condition. After 6 months of follow-up, the patient has not experienced any further acute pain episodes.ConclusionThis case highlights the potential therapeutic effect of upadacitinib sustained-release tablets during the acute phase of chronic refractory gouty arthritis. |
| first_indexed | 2024-04-24T17:36:27Z |
| format | Article |
| id | doaj.art-b45ffd79675a44f18b2c9d30ffb19a7b |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-24T17:36:27Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-b45ffd79675a44f18b2c9d30ffb19a7b2024-03-28T04:54:19ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-03-011110.3389/fmed.2024.13571171357117Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature reviewLishi Yu0Weidong Huang1Honghua Lv2Lie Jin3Wenhui Lei4Department of Rheumatology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, ChinaDepartment of Nephrology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, ChinaDepartment of Rheumatology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, ChinaDepartment of Nephrology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, ChinaDepartment of Nephrology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, ChinaBackgroundGouty arthritis (GA) is a crystal-related joint disease caused by the deposition of monosodium urate (MSU) crystals, directly associated with hyperuricemia resulting from purine metabolism disorder and/or reduced uric acid excretion. Acute attacks of typical gouty arthritis are generally relieved through the clinical use of NSAIDs, colchicine, or glucocorticoids. However, managing patients with chronic refractory gout poses challenges due to complications such as multiple tophi, gouty nephropathy, diabetes, and gastrointestinal bleeding. While there have been numerous studies on gout in recent years, research specifically regarding chronic refractory gout remains limited. The management of such cases still faces several unresolved issues, including recurrent disease flare-ups and poor patient compliance leading to inadequate drug utilization and increased risk of side effects. In this report, we present a case of successful improvement in chronic refractory gouty arthritis using the biologic agent upadacitinib sustained-release tablets.Case presentationOur case report involves a 53 years-old Asian patient with recurrent gouty arthritis who had a history of over 20 years without regular treatment, presenting with tophi and an increasing number of painful episodes. During hospitalization, various analgesics and anti-inflammatory drugs provided inadequate relief, requiring the use of steroids to alleviate symptoms. However, tapering off steroids proved challenging. We decided to add upadacitinib sustained-release tablets to the treatment regimen, which ultimately improved the patient’s condition. After 6 months of follow-up, the patient has not experienced any further acute pain episodes.ConclusionThis case highlights the potential therapeutic effect of upadacitinib sustained-release tablets during the acute phase of chronic refractory gouty arthritis.https://www.frontiersin.org/articles/10.3389/fmed.2024.1357117/fullgoutarthritisgouty arthritistreatmentupadacitinib sustained-release tablets |
| spellingShingle | Lishi Yu Weidong Huang Honghua Lv Lie Jin Wenhui Lei Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review Frontiers in Medicine gout arthritis gouty arthritis treatment upadacitinib sustained-release tablets |
| title | Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review |
| title_full | Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review |
| title_fullStr | Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review |
| title_full_unstemmed | Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review |
| title_short | Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review |
| title_sort | upadacitinib sustained release tablets for the treatment of chronic refractory gouty arthritis a case report and literature review |
| topic | gout arthritis gouty arthritis treatment upadacitinib sustained-release tablets |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1357117/full |
| work_keys_str_mv | AT lishiyu upadacitinibsustainedreleasetabletsforthetreatmentofchronicrefractorygoutyarthritisacasereportandliteraturereview AT weidonghuang upadacitinibsustainedreleasetabletsforthetreatmentofchronicrefractorygoutyarthritisacasereportandliteraturereview AT honghualv upadacitinibsustainedreleasetabletsforthetreatmentofchronicrefractorygoutyarthritisacasereportandliteraturereview AT liejin upadacitinibsustainedreleasetabletsforthetreatmentofchronicrefractorygoutyarthritisacasereportandliteraturereview AT wenhuilei upadacitinibsustainedreleasetabletsforthetreatmentofchronicrefractorygoutyarthritisacasereportandliteraturereview |